Wuhan Keqian Biology Co. Ltd. Reports Findings in Feline Panleukopenia Virus (Development of a recombinant Lactobacillus plantarum oral vaccine expressing VP2 protein for preventing feline panleukopenia virus).

A report from Wuhan Keqian Biology Co. Ltd. in Wuhan, People's Republic of China, discusses the development of a recombinant Lactobacillus plantarum oral vaccine for preventing feline panleukopenia virus (FPV). Traditional vaccines for FPV can induce stress and adverse reactions, so there is a need for a safer and more gentle vaccination method. The study found that the recombinant L. plantarum NC8/VP2 effectively colonizes the feline intestinal tract and induces high levels of neutralizing antibodies through oral administration. This research presents a promising approach for disease prevention in domestic cats. [Extracted from the article]